Maria Giovanna Trivieri,Philip M Robson,Vittoria Vergani,Gina LaRocca,Angelica M Romero-Daza,Ronan Abgral,Ana Devesa,Levi-Dan Azoulay,Nicolas A Karakatsanis,Aditya Parikh,Christia Panagiota,Anna Palmisano,Louis DePalo,Helena L Chang,Joseph H Rothstein,Rima A Fayad,Marc A Miller,Valentin Fuster,Jagat Narula,Marc R Dweck,Adam Morgenthau,Adam Jacobi,Maria Padilla,Jason C Kovacic,Zahi A Fayad,Philip M. Robson,Angelica M. Romero-Daza,Nicolas A. Karakatsanis,Helena L. Chang,Joseph H. Rothstein,Rima A. Fayad,Marc A. Miller,Marc R. Dweck,Jason C. Kovacic,Zahi A. Fayad

Abstract:BACKGROUND: Imaging with late gadolinium enhancement (LGE) magnetic resonance (MR) and 18F-fluorodeoxyglucose (18F-FDG) PET allows complementary assessment of myocardial injury and disease activity and has shown promise for improved characterization of active cardiac sarcoidosis (CS) based on the combined positive imaging outcome, MR(+)PET(+).OBJECTIVES: This study aims to evaluate qualitative and quantitative assessments of hybrid MR/PET imaging in CS and to evaluate its association with cardiac-related outcomes.METHODS: A total of 148 patients with suspected CS underwent hybrid MR/PET imaging. Patients were classified based on the presence/absence of LGE (MR+/MR-), presence/absence of 18F-FDG (PET+/PET-), and pattern of 18F-FDG uptake (focal/diffuse) into the following categories: MR(+)PET(+)FOCAL, MR(+)PET(+)DIFFUSE, MR(+)PET(-), MR(-)PET(+)FOCAL, MR(-)PET(+)DIFFUSE, MR(-)PET(-). Further analysis classified MR positivity based on %LGE exceeding 5.7% as MR(+/-)5.7%. Quantitative values of standard uptake value, target-to-background ratio, target-to-normal-myocardium ratio (TNMRmax), and T2 were measured. The primary clinical endpoint was met by the occurrence of cardiac arrest, ventricular tachycardia, or secondary prevention implantable cardioverter-defibrillator (ICD) before the end of the study. The secondary endpoint was met by any of the primary endpoint criteria plus heart failure or heart block. MR/PET imaging results were compared between those meeting or not meeting the clinical endpoints.RESULTS: Patients designated MR(+)5.7%PET(+)FOCAL had increased odds of meeting the primary clinical endpoint compared to those with all other imaging classifications (unadjusted OR: 9.2 [95% CI: 3.0-28.7]; P = 0.0001), which was higher than the odds based on MR or PET alone. TNMRmax achieved an area under the receiver-operating characteristic curve of 0.90 for separating MR(+)PET(+)FOCAL from non-MR(+)PET(+)FOCAL, and 0.77 for separating those reaching the clinical endpoint from those not reaching the clinical endpoint.CONCLUSIONS: Hybrid MR/PET image-based classification of CS was statistically associated with clinical outcomes in CS. TNMRmax had modest sensitivity and specificity for quantifying the imaging-based classification MR(+)PET(+)FOCAL and was associated with outcomes. Use of combined MR and PET image-based classification may have use in prognostication and treatment management in CS.

Speckle tracking echocardiography can predict subclinical myocardial involvement in patients with sarcoidosis: A meta‐analysis

Speckle‐Tracking Echocardiography as an Effective Screening Tool for Cardiac Involvement Among Patients With Systemic Sarcoidosis in an Indian Cohort: A Prospective Observational Study

The usefulness of speckle tracking echocardiography for the prediction of cardiac involvement in patients with biopsy‐proven sarcoidosis

Echocardiographic evaluation of left ventricular mechanics in sarcoidosis patients without overt heart disease: a systematic review and meta-analysis

Prognostic value of multimodality imaging in the contemporary management of cardiac sarcoidosis

Diagnosis Algorithm of Cardiac Sarcoidosis: Where Are We?

Assessment of a new index of myocardial strain for the diagnosis of cardiac sarcoidosis

Cardiac Involvement Assessment in Systemic Sclerosis Using Speckle Tracking Echocardiography: a Systematic Review and Meta-Analysis

Contemporary Diagnostics of Cardiac Sarcoidosis: The Importance of Multimodality Imaging

Holter Monitoring and Cardiac Biomarkers in Screening for Cardiac Sarcoidosis

Comprehensive cardiovascular magnetic resonance assessment in patients with sarcoidosis and preserved left ventricular ejection fraction

Revealing The Enigma Of Cardiac Sarcoidosis: The Crucial Significance Of Advanced Imaging Modalities- A Case Report

Myocardial contractile patterns predict future cardiac events in sarcoidosis

Subclinical Myocardial Dysfunction Assessment Using Speckle Tracking Echocardiography in Patients With Psoriasis: A Pilot Meta‐Analysis

Clinical assessment of cardiac impairment favored by two-dimensional speckle tracking echocardiology in patients with systemic sclerosis

Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis

Hybrid Magnetic Resonance Positron Emission Tomography Is Associated With Cardiac-Related Outcomes in Cardiac Sarcoidosis

Evaluation of myocardial work indexes in patients with cardiac sarcoidosis

CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis

Specific locations of myocardial inflammation and fibrosis are associated with higher risk of events in cardiac sarcoidosis

Pre-Treatment Myocardial 18FDG Uptake Predicts Response to Immunosuppression in Patients With Cardiac Sarcoidosis